AETHLON MEDICAL INC financial data

Symbol
AEMD on Nasdaq
Location
San Diego, CA
Fiscal year end
31 March
Latest financial report
10-Q - Q4 2025 - 12 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 378% % 9.3%
Debt-to-equity 34% % -18%
Return On Assets -164% % -51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,315,110 shares -91%
Common Stock, Shares, Outstanding 973,213 shares -93%
Entity Public Float $6,650,000 USD 21%
Common Stock, Value, Issued $973 USD -93%
Weighted Average Number of Shares Outstanding, Basic 823,126 shares 372%
Weighted Average Number of Shares Outstanding, Diluted 823,126 shares 372%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $2,647,125 USD 72%
General and Administrative Expense $2,714,880 USD -18%
Operating Income (Loss) $7,367,977 USD 25%
Net Income (Loss) Attributable to Parent $11,522,096 USD -21%
Earnings Per Share, Basic 13.3 USD/shares 76%
Earnings Per Share, Diluted 13.3 USD/shares 76%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,956,397 USD 44%
Assets, Current $7,141,519 USD 44%
Property, Plant and Equipment, Net $434,179 USD -43%
Operating Lease, Right-of-Use Asset $382,583 USD -43%
Assets $8,057,128 USD 23%
Accounts Payable, Current $469,452 USD -23%
Liabilities, Current $1,257,137 USD -29%
Operating Lease, Liability, Noncurrent $86,894 USD -79%
Liabilities $1,344,031 USD -39%
Accumulated Other Comprehensive Income (Loss), Net of Tax $29,837 USD -75%
Retained Earnings (Accumulated Deficit) $173,222,020 USD -7.1%
Stockholders' Equity Attributable to Parent $6,713,097 USD 55%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $5,766,332 USD -62%
Liabilities and Equity $8,057,128 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,714,937 USD 1.9%
Net Cash Provided by (Used in) Financing Activities $5,357 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 6,000,000 shares -90%
Common Stock, Shares, Issued 973,213 shares -93%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,735,790 USD -148%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,055,106 USD 44%
Deferred Tax Assets, Valuation Allowance $34,398,000 USD 3.4%
Deferred Tax Assets, Gross $34,398,000 USD 3.4%
Operating Lease, Liability $417,522 USD -42%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid $676,815 USD -32%
Property, Plant and Equipment, Gross $1,655,109 USD -17%
Operating Lease, Liability, Current $330,628 USD 7.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $343,353 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $333,462 USD 3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $27,064 USD -55%
Lessee, Operating Lease, Liability, to be Paid, Year Three $343,352 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $30,022,000 USD 11%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $179,963,981 USD 8.4%
Depreciation, Depletion and Amortization $82,637 USD -4%
Deferred Tax Assets, Net of Valuation Allowance $0 USD